WO2009043525A3 - Use of the combination of gluten exorphin c and cd36 as a therapeutic agent - Google Patents

Use of the combination of gluten exorphin c and cd36 as a therapeutic agent Download PDF

Info

Publication number
WO2009043525A3
WO2009043525A3 PCT/EP2008/008108 EP2008008108W WO2009043525A3 WO 2009043525 A3 WO2009043525 A3 WO 2009043525A3 EP 2008008108 W EP2008008108 W EP 2008008108W WO 2009043525 A3 WO2009043525 A3 WO 2009043525A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
combination
therapeutic agent
asn
tyr
Prior art date
Application number
PCT/EP2008/008108
Other languages
French (fr)
Other versions
WO2009043525A2 (en
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Lab Ag
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Lab Ag, Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher filed Critical Mondobiotech Lab Ag
Publication of WO2009043525A2 publication Critical patent/WO2009043525A2/en
Publication of WO2009043525A3 publication Critical patent/WO2009043525A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the use of the combination of the peptide compounds Tyr-Arg-Val-Arg-Phe-Leu-Ala-Lys-Glu-Asn-Val-Thr-Gln-Asp-Ala-Glu-Asp-Asn-Cys-OH and Tyr-Pro-lle-Ser-Leu-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
PCT/EP2008/008108 2007-09-11 2008-09-09 Use of the combination of gluten exorphin c and cd36 as a therapeutic agent WO2009043525A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017748.0 2007-09-11
EP07017753 2007-09-11
EP07017753.0 2007-09-11
EP07017748 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009043525A2 WO2009043525A2 (en) 2009-04-09
WO2009043525A3 true WO2009043525A3 (en) 2009-08-13

Family

ID=40526752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008108 WO2009043525A2 (en) 2007-09-11 2008-09-09 Use of the combination of gluten exorphin c and cd36 as a therapeutic agent

Country Status (1)

Country Link
WO (1) WO2009043525A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106860855B (en) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 Application of polypeptide and polypeptide derivative in preventing and treating fibrotic diseases

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12011475B2 (en) 2017-03-01 2024-06-18 Chengdu Huitai Biomedicine Co., Ltd. Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
CN112386678B (en) * 2019-08-13 2023-07-07 成都惠泰生物医药有限公司 Use of polypeptides or derivatives thereof
CN117637185B (en) * 2024-01-25 2024-04-23 首都医科大学宣武医院 Image-based craniopharyngeal tube tumor treatment auxiliary decision-making method, system and equipment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006849A1 (en) * 1991-10-03 1993-04-15 The Center For Blood Research Binding of plasmodium falciparum-infected erythrocytes to cd36
WO1996036349A1 (en) * 1995-05-17 1996-11-21 Manitoba Cancer Treatment And Research Foundation POST-TRANSLATIONAL ACTIVATION OF TGF-β1 INVOLVING THE TSP-1 RECEPTOR CD36
WO2004064858A1 (en) * 2003-01-23 2004-08-05 Nihon University School Juridical Person Drug containing human arterial natriuretic peptide
US20050113297A1 (en) * 2003-08-22 2005-05-26 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2006074114A2 (en) * 2005-01-03 2006-07-13 Yu Ruey J Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006849A1 (en) * 1991-10-03 1993-04-15 The Center For Blood Research Binding of plasmodium falciparum-infected erythrocytes to cd36
WO1996036349A1 (en) * 1995-05-17 1996-11-21 Manitoba Cancer Treatment And Research Foundation POST-TRANSLATIONAL ACTIVATION OF TGF-β1 INVOLVING THE TSP-1 RECEPTOR CD36
WO2004064858A1 (en) * 2003-01-23 2004-08-05 Nihon University School Juridical Person Drug containing human arterial natriuretic peptide
US20050113297A1 (en) * 2003-08-22 2005-05-26 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2006074114A2 (en) * 2005-01-03 2006-07-13 Yu Ruey J Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 2004-571624 *
DUBYNIN, V. A. (REPRINT) BELYAEVA, YU. A. ET AL: "Neurotropic activity of exorphins with different affinity to the opioid receptors of mu and delta-types", NEUROCHEMICAL JOURNAL, (JAN-JUN 2008) VOL. 2, NO. 1-2, PP. 47-52. ISSN: 1819-7124. PB - MAIK NAUKA/INTERPERIODICA/SPRINGER, 233 SPRING ST, NEW YORK, NY 10013-1578 USA., 2008, XP002530124 *
ERTAY T ET AL: "99mTc-exorphin C: A new peptide radiopharmaceutical for tumor imaging", JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 265, no. 3, 1 August 2005 (2005-08-01), pages 473 - 479, XP019252074, ISSN: 1588-2780 *
ERTAY T ET AL: "Scintigraphic imaging with <99m>Tc- exorphin C in rabbits", APPLIED RADIATION AND ISOTOPES, ELSEVIER, OXFORD, GB, vol. 62, no. 6, 1 June 2005 (2005-06-01), pages 883 - 888, XP004810520, ISSN: 0969-8043 *
FEBBRAIO M ET AL: "CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 108, no. 6, 1 September 2001 (2001-09-01), pages 785 - 791, XP002487577, ISSN: 0021-9738 *
FUKUDOME S I ET AL: "Gluten exorphin C", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 316, no. 1, 18 January 1993 (1993-01-18), pages 17 - 19, XP025576409, ISSN: 0014-5793, [retrieved on 19930118] *
YEHUALAESHET TESHOME ET AL: "A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 23, no. 2, August 2000 (2000-08-01), pages 204 - 212, XP002530510, ISSN: 1044-1549 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106860855B (en) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 Application of polypeptide and polypeptide derivative in preventing and treating fibrotic diseases

Also Published As

Publication number Publication date
WO2009043525A2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2009033821A3 (en) Use of a peptide as a therapeutic agent
WO2009043522A3 (en) Use of a peptide as a therapeutic agent
WO2009043518A3 (en) Use of a combination of cart peptides as a therapeutic agent
LTPA2017015I1 (en) Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2006058867A3 (en) Substituted pteridines for the treatment of inflammatory diseases
IL184125A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2010088527A3 (en) Peptides and nanoparticles for therapeutic and diagnostic applications
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2009033818A3 (en) Use of a peptide as a therapeutic agent
WO2009033813A3 (en) Use of a peptide as a therapeutic agent
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
WO2009033820A3 (en) Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
WO2009043519A3 (en) Use of band 3 protein and pacap-27 as a therapeutic agent
WO2009043523A3 (en) Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
WO2009046872A3 (en) Use of a peptide as a therapeutic agent
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802583

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802583

Country of ref document: EP

Kind code of ref document: A2